达普托米辛通过降低RPS19的表达来抑制多发性骨髓瘤的进展
Yijun Zhuang1, Yin Zhang1, Caiyun Chen1
1Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, Fujian, China.
Combinatorial chemistry & high throughput screening
|March 8, 2024
概括
达普托米辛 (DAP) 对多发性骨髓瘤 (MM) 细胞表现出抗癌作用. DAP抑制了MM细胞的增殖和迁移,同时促进了细胞灭绝,为这种血液性恶性瘤提供了潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 多发性骨髓瘤 (MM) 是一种流行的血细胞恶性瘤.
- 现有的MM治疗方法存在局限性,需要新的治疗策略.
- 在MM中,达普素 (DAP) 的抗瘤潜力尚未得到充分证实.
研究的目的:
- 为了研究达普素 (DAP) 对RPMI 8226多发性骨髓瘤 (MM) 细胞系的抗癌作用.
- 阐明DAP潜在的抗MM活性背后的机制.
主要方法:
- 在RPMI 8226 MM细胞中,用不同度的DAP (20μM,40μM,80μM) 进行了治疗.
- 博尔特佐米布 (BZ) 被用作阳性对照.
- 细胞增殖,细胞亡,细胞周期,迁移和入侵被评估使用CCK8,流细胞计和透孔测定.
- 分析了RPS19的mRNA和蛋白质表达水平.
主要成果:
- DAP显著抑制了MM细胞的增殖和诱导的亡.
- DAP治疗导致G1阶段细胞周期停止.
- RPMI 8226细胞的迁移和入侵能力被DAP降低.
- DAP降低了MM细胞中RPS19的mRNA和蛋白质表达.
结论:
- 达普托米辛通过抑制增殖,迁移和入侵而表现出显著的抗多发性骨髓瘤效应,同时促进细胞亡.
- 观察到的DAP的抗MM效应与RPS19表达的下调有关.
- 在多发性骨髓瘤治疗中,DAP是新型治疗药物开发的有希望的候选者.
关键词:
多发性骨髓瘤是一种多发性骨髓瘤.在RPS19中使用.灭症 (apoptosis) 是一种死亡的过程.博尔特佐米布 (Bortezomib) 是一种药物.细胞. 细胞. 细胞.达普米辛是一种菌素.更多相关视频
09:47Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
Published on: May 10, 2022
2.6K
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.8K
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
